Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Scalambra

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Biomedicines|October 27, 2022
Prevention and Therapy of Metastatic HER-2<sup>+</sup> Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle VaccineFrancesca Ruzzi, Arianna Palladini, Stine Clemmensen, et al.
Translational Lung Cancer Research|December 15, 2022
ADK-VR2, a cell line derived from a treatment-naïve patient with <i>SDC4-ROS1</i> fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLCFrancesca Ruzzi, Stefania Angelicola, Lorena Landuzzi, et al.
Scientific Reports|January 16, 2021
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograftLorena Landuzzi, Arianna Palladini, Claudio Ceccarelli, et al.
Journal of Translational Medicine|January 3, 2025
PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD)Stefania Angelicola, Francesca Giunchi, Francesca Ruzzi, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Biomedicines|October 27, 2022
Prevention and Therapy of Metastatic HER-2<sup>+</sup> Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle VaccineFrancesca Ruzzi, Arianna Palladini, Stine Clemmensen, et al.
Translational Lung Cancer Research|December 15, 2022
ADK-VR2, a cell line derived from a treatment-naïve patient with <i>SDC4-ROS1</i> fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLCFrancesca Ruzzi, Stefania Angelicola, Lorena Landuzzi, et al.
Scientific Reports|January 16, 2021
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograftLorena Landuzzi, Arianna Palladini, Claudio Ceccarelli, et al.
Journal of Translational Medicine|January 3, 2025
PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD)Stefania Angelicola, Francesca Giunchi, Francesca Ruzzi, et al.
Pageof 2